Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CBLB
REST API REST API
Homo sapiens
CBLB is differentially expressed in 349 experiments: 161 organism parts: bone marrow, mammary gland, ... (159 more);, 225 disease states: normal, prostate carcinoma, ... (223 more);, 117 cell types 425 cell lines 49 compound treatments and 78 other conditions.
Synonyms RNF56, Cbl-b
Orthologs ENSCING00000002655 (Ciona intestinalis)   Cblb (Rattus norvegicus)   CBLB (Gallus gallus)   cblb (Danio rerio)   CBLB (Bos taurus)   Cblb (Mus musculus)   Cbl (Drosophila melanogaster)   CBLB (Xenopus laevis)   CBLB (Canis familiaris)   (Compare orthologs)
Gene Ontology Term ligase activity, protein binding, cytoplasm, intracellular, membrane raft, NLS-bearing substrate import into nucleus, signal transducer activity, cell surface receptor linked signaling pathway, protein kinase binding, nucleus, response to hormone stimulus, ubiquitin-protein ligase activity, immune response, response to gravity, signal transduction, calcium ion binding, zinc ion binding, positive regulation of protein catabolic process, T cell activation, negative regulation of T cell receptor signaling pathway, phosphotyrosine binding, negative regulation of alpha-beta T cell proliferation, positive regulation of T cell anergy, intracellular signal transduction, regulation of signaling
InterPro Term UBA/transl_elong_EF1B_N_euk, UBA/transl_elong_EF1B_N, Znf_RING, Znf_C3HC4_RING-type, Adaptor_Cbl_SH2-like, Adaptor_Cbl_EF_hand-like, Adaptor_Cbl_N_hlx
UniProt Accession Q13191, B5MC15, A8K9S7, C9JRB3, Q68CY2, C9JU85, E7ENW2, E9PHA9, F5H4J9
Search EB-eye ENSG00000114423
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (34 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (37 experiments)

Factor Value U/D Experiments
SW480
4
E-MTAB-37, E-MEXP-1014, E-GEOD-18005, E-GEOD-2509
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
BT474
2
E-MEXP-440, E-MTAB-37
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
T47D
2
E-MEXP-440, E-MTAB-62
419 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, E-GEOD-2822, ... (59 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-TABM-145, E-GEOD-6740
macrophage
2
E-GEOD-8286, E-GEOD-5099
CD14+ monocyte
2
E-MEXP-1600, E-AFMX-5
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
fibroblast
1
2
E-GEOD-3920, E-MEXP-466, E-GEOD-3204
111 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-MEXP-1121, E-GEOD-1577, E-MEXP-2280, ... (70 experiments)

Factor Value U/D Experiments
head and neck squamous cell carcinoma
3
E-MTAB-62, E-GEOD-6631, E-GEOD-2379
prostate carcinoma
1
3
E-MEXP-2034, E-MTAB-62, E-GEOD-5377, E-MTAB-37
dermatomyositis
2
E-GEOD-5370, E-GEOD-1551
astrocytoma
2
E-GEOD-4290, E-MTAB-37
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
chronic lymphocytic leukemia
2
E-MTAB-37, E-GEOD-6691
219 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-1417, E-TABM-782, E-GEOD-3720, E-MEXP-2590, ... (29 experiments)

Factor Value U/D Experiments
ponasterone A
1
E-GEOD-3113
M-CSF
1
1
E-GEOD-5099
BCR/FGFR1
1
1
E-GEOD-15811
control - untreated
1
E-GEOD-7216
mercaptopurine, methotrexate
1
E-GEOD-412
platelet-derived growth factor
1
E-GEOD-1923
43 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
58
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-GEOD-22513, E-GEOD-860, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-1059, E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-GEOD-2152, E-MEXP-1996, E-GEOD-17476, E-GEOD-21750, E-TABM-868, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, E-MEXP-1273, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-1926, E-MEXP-2069, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Labeling
studied in E-LGCL-5

Library source
studied in E-GEOD-19323

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1493, E-GEOD-21750, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (10 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-2508, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-23984

Strain or line
studied in E-MEXP-1996

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-22541

Processing time: 0.351 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM